Observational studyRheumatology (Oxford, England)2015
Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies.
Registry-linked trialOpen access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Rheumatology (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01294696 (Survey of Osteoarthritis Real World Therapies), which is not on this map. Cited by 69 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 5 pooled it
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Survey of Osteoarthritis Real World Therapies (SORT)
Who cites it
69 citing papers in PubMed, 5 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Association of knee and hip osteoarthritis with the risk of falls and fractures: a systematic review and meta-analysis.Arthritis research & therapy · 2023Pooled it
- Mirtazapine for fibromyalgia in adults.The Cochrane database of systematic reviews · 2018Pooled it
- Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.PharmacoEconomics · 2016Pooled it
- High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications.Arthritis research & therapy · 2016Pooled it
- Effects of Tai Chi combined with transcranial direct current stimulation on pain in knee osteoarthritis: a randomized controlled neuroimaging trial.BMC medicine · 2026Trial
- Trial
- A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients - ZAP2.BMC musculoskeletal disorders · 2018Trial
- Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study.The Journal of bone and joint surgery. American volume · 2018Trial
- Isothiocyanates are detected in human synovial fluid following broccoli consumption and can affect the tissues of the knee joint.Scientific reports · 2017Trial
- Massage Therapy and Quality of Life in Osteoarthritis of the Knee: A Qualitative Study.Pain medicine (Malden, Mass.) · 2017Trial
- Spironolactone for People Age 70 Years and Older With Osteoarthritic Knee Pain: A Proof-of-Concept Trial.Arthritis care & research · 2016Trial
- Retrospective Comparison of Short- and Mid-Term Performance of 200-µm Polyethylene Glycol Microspheres vs Ethiodized Oil Emulsion for Genicular Artery Embolization in Symptomatic Knee Osteoarthritis.Cardiovascular and interventional radiology · 2026Article
- Observational
- The development of a cannabis risk assessment tool for patients with rheumatologic conditions: a Delphi study.Clinical rheumatology · 2026Article
- Expert consensus on glucocorticoids injection for knee osteoarthritis.Journal of orthopaedic surgery and research · 2026Article
- Nanozyme-Mediated Joint Homeostasis Restoration: Emerging Strategies for Arthritis Therapy.International journal of nanomedicine · 2026Review
- Sex-Related Differences in Chronic Pain: A Narrative Review by a Multidisciplinary Task Force.Medicina (Kaunas, Lithuania) · 2025Review
- Radiofrequency treatment for chronic knee pain in people with knee osteoarthritis.The Cochrane database of systematic reviews · 2025Article
- 9. Chronic knee pain.Pain practice : the official journal of World Institute of Pain · 2025Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
Paul M PelosoLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
Sharlette V EverettLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
Srinivasan RajagopalanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
Christopher M BlackLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
Panagiotis MavrosLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
Nigel K ArdenLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
Ceri J PhillipsLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
François RannouLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
Mart A F J van de LaarLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
R Andrew MooreLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.
Stephanie D TaylorLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK. stephanie_taylor@merck.com.
University of Oxford · GBHôpital Cochin · FR
Funding
Medical Research Council MR/L01629X/1
Abstract
objectiveTo estimate the prevalence of inadequate pain relief (IPR) among patients with symptomatic knee OA prescribed analgesic therapy and to characterize patients with IPR.
methodsPatients ≥50 years old with physician-diagnosed knee OA who had taken topical or oral pain medication for at least 14 days were recruited for this prospective non-interventional study in six European countries. Pain and function were assessed using the Brief Pain Inventory (BPI) and the WOMAC; quality of life (QoL) was assessed using the 12-item short form. IPR was defined as an average pain score of >4 out of 10 on BPI question 5.
resultsOf 1187 patients enrolled, 68% were female and the mean age was 68 years (s.d. 9); 639 (54%) met the definition of IPR. Patient responses for the BPI average pain question were well correlated with responses on the WOMAC pain subscale (Spearman r = 0.64, P < 0.001). In multivariate logistic regression, patients with IPR had greater odds of being female [adjusted odds ratio (adjOR) 1.90 (95% CI 1.46, 2.48)] and having OA in both knees [adjOR 1.48 (95% CI 1.15, 1.90)], higher BMI, longer OA duration, depression or diabetes. Patients with IPR (vs non-IPR) were more likely to have worse QoL, greater function loss and greater pain interference.
conclusionIPR is common among patients with knee OA requiring analgesics and is associated with large functional loss and impaired QoL. Patients at particular risk of IPR, as characterized in this study, may require greater attention towards their analgesic treatment options.
trial registrationhttps://clinicaltrials.gov/ (NCT01294696).
Indexed as
Administration, CutaneousAdministration, OralAgedAnalgesicsFemaleHumansMaleMusculoskeletal PainOsteoarthritis, KneePain MeasurementPatient SatisfactionProspective StudiesQuality of LifeTreatment OutcomeAnalgesicsanalgesic therapyinadequate pain reliefkneeosteoarthritis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT01294696ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.